Conclusions: Among patients selected for AF ablation, those with and without CKD had similar rates of postprocedural complications although they were more likely to be re-admitted for heart failure. CKD was not independently associated with AF hospitalization, cardioversion, and repeat ablation. These findings can inform clinical decision-making in patients with
Introduction
Atrial fibrillation (AF) and chronic kidney disease (CKD) are common comorbid conditions with a complex relationship. 1, 2 In addition to sharing common risk factors such as increased age, hypertension, and diabetes, presence of CKD independently increases the risk for development of AF. 3 Patients with CKD and AF are also at increased risk of stroke and anticoagulation-associated hemorrhage. 4, 5 Furthermore, AF may accelerate deterioration of kidney function, 6 while maintenance of sinus rhythm may preserve or improve it. 7 A recent European Heart Rhythm Association position paper highlights the current evidence gap regarding management of AF in the context of CKD. 8 As most large AF studies exclude patients with functionally significant kidney disease, 3 there is limited data regarding safety of agents commonly used for rate and rhythm control. 8 Consequently, catheter-based AF ablation is an attractive treatment option for AF patients with CKD. However, only small studies from Japan and China (16-232 patients) [9] [10] [11] [12] [13] have examined AF ablation in CKD cohorts, suggesting a high rate of AF recurrence after ablation, but with few insights into other postprocedural outcomes. We therefore performed a retrospective cohort study using commercial health insurance claims of U.S. patients undergoing catheter ablation for AF to report the associations of CKD with common 30-day complications and 1-year clinical outcomes.
Methods
We analyzed data from the Truven Health MarketScan Commercials Claims and Encounters and Medicare Supplemental Databases (Truven Health Analytics Inc., Ann Arbor, MI, USA). Linked and merged datasets included the Inpatient Admissions file, which contains all diagnoses and procedures in the service records related to a hospital admission; the Outpatient Services file, which contains information on encounters and claims for services delivered at a doctor's office, hospital outpatient facility, emergency room, or other outpatient facility; and the Outpatient Pharmaceutical Claims file, which includes complete records of mail-order or card program prescription drug claims. The study was approved by the local Institutional Review Board prior to analysis.
We identified all adult patients with nonvalvular AF who received a catheter ablation between January 1, 2007 and December 31, 2011 (Fig. 1 These diagnostic codes were chosen to be specific to CKD in order to avoid misclassification of non-CKD patients as those with CKD. We did not use codes for acute kidney injury. Previous work has shown that this selected strategy has a sensitivity of 0.52, specificity of 0.99, positive predictive value of 0.32, and negative predictive value of 0.99 for comorbidity ascertainment in the context of cardiovascular procedures. 14, 15 We assessed the safety of AF ablation using 30-day postprocedural complications based on common diagnosis and procedure codes identified by previous investigators. 16, 17 These included all-cause hospitalizations, vascular complications, hematoma or hemorrhage, cardiac perforation or tamponade, pneumothorax or hemothorax, stroke or transient ischemic attack (TIA), pacemaker implantation, implantable cardioverter defibrillator (ICD) implantation, heart failure (HF), and in-hospital death. For all-cause hospitalizations, we searched inpatient datasets for any admissions occurring in the 30 days after the index ablation. Similarly, for all other 30-day complications, we searched for relevant ICD-9 and CPT-4 codes in the inpatient dataset within the first 30 days after the ablation date. We also evaluated the following clinical outcomes: time to hospitalization for AF, time to cardioversion, and time to repeat ablation in the first year after index catheter AF ablation. For the endpoint of AF hospitalization, we considered any inpatient encounter associated with a primary diagnosis for AF that occurred after the initial inpatient or outpatient AF ablation procedure. Cardioversion and repeat ablation for AF at 1 year were ascertained based on CPT-4 codes for each procedure in both inpatient and outpatient datasets. Secondary outcomes at 1 year included hospitalization for all-causes, myocardial infarction (MI) or unstable angina, HF, supraventricular tachycardia, ventricular arrhythmia, stroke/TIA, intracranial hemorrhage, and syncope.
Clinical Covariates
Patient baseline comorbidities were determined using comorbidity-specific ICD-9 codes up to 1 year prior to the catheter ablation date, based on the Agency for Healthcare Research and Quality (AHRQ) Clinical Classification System. 4 We additionally assessed comorbidity using the Charlson and Selim Comorbidity Indices and assessed stroke risk using the CHADS 2 and CHA 2 DS 2 -VASc scores. Pharmacological therapies received in the 120 days prior to AF ablation were ascertained using the MarketScan R Outpatient Pharmaceutical Claims file.
Statistical Analysis
We compared differences in baseline characteristics and 30-day complications between CKD and non-CKD groups using t-tests for continuous variables and chi-square tests and Fisher's exact tests for categorical variables. For all primary and secondary outcomes at 1 year, we calculated incidence rates for the first event in each patient by dividing the number of events by total person-years of follow-up for each group.
Cox proportional hazards regression was used to examine the association between CKD and each outcome at 1 year. In the full multivariate model, we adjusted for age, sex, Charlson Comorbidity Index score, HF, hypertension, diabetes, stroke/TIA, prior MI, anemia, peripheral artery disease (PAD) or vascular disease, chronic obstructive pulmonary disease (COPD), sleep apnea, year of ablation, insurance plan, and receipt of concomitant drug therapies (warfarin, dabigatran, clopidogrel, Class I and Class III antiarrhythmic drugs, amiodarone, beta blockers, and calcium channel blockers). We also used the Kaplan-Meier method and log-rank tests to calculate differential probability of event-free survival using the composite endpoint of AF hospitalization, cardioversion, or repeat AF ablation within 1 year. All analyses were performed using SAS, version 9.1 (Cary, NC, USA) and STATA, version 11.0 (College Station, TX, USA).
Results
The study cohort included 21,091 patients (59.2 ± 10.9 years, 73.7% with age <65 years) that received a catheter ablation for AF between 2007 and 2011; 29.1% were women and 7.6% had a diagnosis code for CKD. There were 61 patients on dialysis. Ablation recipients with CKD were older than those without kidney disease (64 years vs. 59 years, P < 0.001; Table 1 ), driven by a larger proportion of CKD patients who were 65-80 years old (34.3% of CKD patients vs. 22.7% in non-CKD, P < 0.001) and >80 years old (7.0% vs. 2.3%, P < 0.001).
The prevalence of baseline comorbidities such as HF, hypertension, diabetes, prior stroke/TIA, PAD, COPD, and obstructive sleep apnea were higher in patients with CKD, which contributed to higher mean scores on both the Charlson (2.7 vs. 0.92, P < 0.001) and Selim (5.3 vs. 2.5, P < 0.001) Comorbidity indices. Patients with CKD also had higher mean CHADS 2 (1.9 vs. 1.0, P < 0.001) and CHA 2 DS 2 -VASc (3.2 vs. 1.8, P < 0.001) scores compared to patients without CKD. At baseline, the proportion of patients receiving class I and class III antiarrhythmic drugs was smaller in patients with CKD, but the proportion of patients receiving amiodarone, statins, diuretics, and ACE-inhibitors or angiotensin receptor blockers was greater in patients with CKD. Receipt of systemic anticoagulants (warfarin, dabigatran) at baseline were lower in patients with CKD (63% vs. 68%, P < 0.001).
30-Day Complications
Seven patients (0.03%) experienced an in-hospital death within 30 days of the index AF ablation, with no significant differences in risk of in-hospital death in patients with or without CKD ( Table 2 ). Rates of vascular complications, hematoma/hemorrhage, stroke/TIA, and cardiac perforation or tamponade were similar in both groups, but heart failure admissions were more common in CKD patients (2.1% vs. 0.4%, P < 0.001). All-cause hospitalization within 30 days was more common in patients with CKD (12.9% vs. 8.5%, P < 0.001).
Cause-Specific Hospitalizations and Outcomes at 1 Year
Patients with CKD had a higher incidence rate and hazard of all-cause hospitalization at 1 year than those without CKD (Table 3) . However, the hazards of AF hospitalization (unadjusted HR: 1.09, 95% CI: 0.95-1.26, P = 0.21; adjusted HR: 1.02, 95% CI: 0.87-1.20, P = 0.79) and cardioversion (unadjusted HR: 1.12, 95% CI: 0.99-1.24, P = 0.07; adjusted HR: 0.99, 95% CI: 0.87-1.12, P = 0.87; Table 3 ) were not significantly higher in patients with CKD. The unadjusted hazard of repeat ablation for AF was significantly lower in patients with CKD (unadjusted HR: 0.82, 95% CI: 0.70-0.95 P = 0.008) but the association was not significant after adjusting for baseline comorbidities and concomitant therapies in the full multivariate model (adjusted HR: 0.89, 95% CI: 0.76-1.06, P = 0.18). Table 4 shows incidence rates and hazards of secondary outcomes at 1-year postablation. The hazards of stroke/TIA did not significantly differ between CKD and non-CKD groups (unadjusted HR: 1.71, 95% CI: 0.96-3.05, P = 0.07; adjusted HR: 0.95, 95% CI: 0.48-1.87, P = 0.88; Table 4 ). However, there were higher unadjusted hazards of hospitalization for all-causes, myocardial infarction/unstable angina, HF, supraventricular tachycardia, ventricular arrhythmia, and intracranial hemorrhage in patients with CKD. After adjusting for baseline comorbidities and drug therapies, patients with CKD were found to have higher hazards of all-cause hospitalization (adjusted HR 1.19, 95%CI: 1.09-1.31, P < 0.001; Table 3 ) and hospitalization for heart failure (adjusted HR: 2.26, 95%CI: 1.74-2.94, P < 0.001; Table 4 ). There were no significant differences in adjusted hazards for MI/unstable angina, supraventricular tachycardia, ventricular arrhythmia, and intracranial hemorrhage between patients with CKD and those without CKD. Cumulative event-free survival, defined as freedom from AF rehospitalization, cardioversion, or repeat AF ablation, was similar in CKD and non-CKD groups. Finally, we compared differences in survival free from AF hospitalization, cardioversion, or repeat AF ablation at 1 year. There was no significant difference in event-free survival based on presence of CKD (log-rank P = 0.62; Fig. 2 ).
Discussion
In this claims cohort analysis of AF ablation in patients with and without chronic kidney disease, we found that patients with CKD experienced similar 30-day complications such as stroke/TIA, perforation/tamponade, and vascular complications but were more likely to be admitted for heart failure. Prior to our analysis, most large studies on AF ablation recipients examined older cohorts and did not measure safety in the context of CKD. These studies have suggested a higher rate of major complications ranging from 5% to 9.1% based on Medicare claims and the California State Inpatient Database. [18] [19] [20] More recently, Deshmukh et al. 17 used data from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) and studied inpatient ablations in 93,801 patients, in whom the overall complication rate was 6.29%. AHRQ has previously noted inconsistencies and incomplete coding for observational services in HCUP data, 21 which could result in ascertainment bias because outpatient encounters are excluded, person-level linkage cannot be performed, and the unit of observation is hospitalization. In contrast, our datasets included full patient-level data from inpatient and outpatient ablations and suggested lower complication rates in patients with and without CKD. There were notably no significant differences in risk of cardiac tamponade with presence of CKD, often cited as the most common ablation-related complication. 22 In-hospital deaths were also infrequent in our cohort (0.03%), similar to rates reported in earlier studies, [18] [19] [20] with no significant differences between CKD and non-CKD patient groups.
At 1 year postablation, our study found an increased risk of all-cause hospitalization in CKD patients, but no increase in risk of AF hospitalization, cardioversion, or repeat AF ablation. Prior to our study, only small retrospective cohort studies have examined clinical outcomes after AF ablation in the context of CKD. In 3 studies, kidney dysfunction was an independent predictor of AF recurrence upon ECG or Holter recordings conducted at 3-month intervals.
9-11 A meta-analysis combining these data reported a significant association between an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m 2 and AF recurrence with at least 1 year of follow-up (pooled HR: 2.32, 95%CI: 1.61-3.35, P < 0.001). 23 Another study examining 702 ablation recipients reported an association between CKD and AF recurrence using a cutpoint of eGFR <68 mL/min/1.73m 2 (HR: 1.43, 95%CI: 1.05-1.95, P = 0.007). 24 Given limitations in our data, we could not directly assess postablation AF recurrence in our cohort, but measured health care utilization associated with AF recurrence after the ablation procedure.
At both 30 days and 1 year, admission for heart failure was more common in ablation recipients with CKD. Congestive heart failure has been increasingly recognized as an acute sequela after AF ablation and may be due to fluid overload in the setting of a noncompliant atrium, poor left atrial function, or diastolic dysfunction. [25] [26] [27] A reduction in fluid delivery with use of low-volume irrigated-tip catheters may have promise in reducing HF complications associated with volume overload, as would tools or techniques that can reduce overall procedure time. 12, 13 On the other hand, impaired renal function is itself a risk factor for both HF and HF hospitalization 6, 7 and higher hospitalization rates could reflect the higher prevalence of HF in the CKD group at baseline, or at least the propensity to retain fluid.
Limitations
Our study has important limitations. These data predated the introduction of CPT codes specific to ablation for AF. Although our algorithm represents a high-specificity approach, it is possible that some ablations could have been performed for arrhythmias other than AF. CKD was ascertained by ICD-9 codes, which could result in misclassification of CKD patients as non-CKD patients and bias results toward the null. Our data sources did not allow us to categorize AF severity (e.g., paroxysmal vs persistent) or to directly measure kidney function. We also could not consider the role of novel oral anticoagulants given the time period of our study. Data regarding periprocedural anticoagulation were limited because claims data capture only prescriptions filled and cannot ascertain cessation or interruption of periprocedural anticoagulation. Finally, our study is restricted to patients with AF who underwent ablation, but does not provide information on who among AF patients was selected for ablation. It is therefore possible that among those with CKD only relatively healthier patients were selected as suitable candidates for the procedure, resulting in confounding by treatment selection. However, it was notable that a significantly higher proportion of older patients (65-80 and >80) received an AF ablation in the CKD patient group compared to the non-CKD group.
Conclusions
Among U.S. patients selected for AF ablation, patients with CKD, compared to those without CKD, were found to have similar rates of common procedural complications, but were more likely to be admitted for heart failure at 30 days and at 1 year. CKD was not independently associated with AF hospitalization, cardioversion, and repeat ablation. These findings may help to inform patient selection and discussion of risks for atrial fibrillation ablation procedures in CKD patients.
